Voss F - Search Results

1

Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.

Deterding R, Griese M, Deutsch G, Warburton D, DeBoer EM, Cunningham S, Clement A, Schwerk N, Flaherty KR, Brown KK, Voss F, Schmid U, Schlenker-Herceg R, Verri D, Dumistracel M, Schiwek M, Stowasser S, Tetzlaff K, Clerisme-Beaty E, Young LR. Deterding R, et al. Among authors: voss f. ERJ Open Res. 2021 Jun 21;7(2):00805-2020. doi: 10.1183/23120541.00805-2020. eCollection 2021 Apr. ERJ Open Res. 2021. PMID: 34164554 Free PMC article.

2

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO^® and OTEMTO^® studies: a subgroup analysis by age.

Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R. Ferguson GT, et al. Among authors: voss f. Int J Chron Obstruct Pulmon Dis. 2016 Oct 31;11:2701-2710. doi: 10.2147/COPD.S108758. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27843306 Free PMC article.

3

Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.

Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L. Buhl R, et al. Among authors: voss f. Respir Med. 2017 Jan;122:58-66. doi: 10.1016/j.rmed.2016.11.011. Epub 2016 Nov 14. Respir Med. 2017. PMID: 27993292 Free article. Clinical Trial.

4

Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.

Ferguson GT, Karpel J, Bennett N, Clerisme-Beaty E, Grönke L, Voß F, Buhl R. Ferguson GT, et al. Among authors: voss f. NPJ Prim Care Respir Med. 2017 Feb 2;27(1):7. doi: 10.1038/s41533-016-0002-x. NPJ Prim Care Respir Med. 2017. PMID: 28154373 Free PMC article. Clinical Trial.

5

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat^® device for maintenance treatment of COPD: comparison with the long-acting β₂-agonist formoterol.

Koch A, Watz H, Maleki-Yazdi MR, Bothner U, Tetzlaff K, Voß F, McGarvey L. Koch A, et al. Among authors: voss f. NPJ Prim Care Respir Med. 2017 Oct 23;27(1):60. doi: 10.1038/s41533-017-0059-1. NPJ Prim Care Respir Med. 2017. PMID: 29061968 Free PMC article. Clinical Trial.

6

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.

Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM; 1305-0013 Trial Investigators. Richeldi L, et al. Among authors: voss f. N Engl J Med. 2022 Jun 9;386(23):2178-2187. doi: 10.1056/NEJMoa2201737. Epub 2022 May 15. N Engl J Med. 2022. PMID: 35569036 Clinical Trial.

7

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.

Bonella F, Cottin V, Valenzuela C, Wijsenbeek M, Voss F, Rohr KB, Stowasser S, Maher TM. Bonella F, et al. Among authors: voss f. Adv Ther. 2022 Jul;39(7):3392-3402. doi: 10.1007/s12325-022-02145-x. Epub 2022 May 14. Adv Ther. 2022. PMID: 35576048 Free PMC article.

8

Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.

Assassi S, Distler O, Allanore Y, Ogura T, Varga J, Vettori S, Crestani B, Voss F, Alves M, Stowasser S, Maher TM; SENSCIS trial investigators. Assassi S, et al. Among authors: voss f. ACR Open Rheumatol. 2022 Oct;4(10):837-844. doi: 10.1002/acr2.11483. Epub 2022 Jul 19. ACR Open Rheumatol. 2022. PMID: 35852465 Free PMC article.

9

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis.

Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM. Richeldi L, et al. Among authors: voss f. J Comp Eff Res. 2022 Dec 20;12(1):e220142. doi: 10.2217/cer-2022-0142. Online ahead of print. J Comp Eff Res. 2022. PMID: 36537726 Free PMC article. Review.

10

Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis.

Maher TM, Stowasser S, Voss F, Bendstrup E, Kreuter M, Martinez FJ, Sime PJ, Stock C. Maher TM, et al. Among authors: voss f. Respirology. 2023 Dec;28(12):1147-1153. doi: 10.1111/resp.14579. Epub 2023 Aug 30. Respirology. 2023. PMID: 37646126 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

196 results

Search Page